Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Epidermal growth factor (EGF) module-containing mucin-like receptor 2 (
EMR2
) is a member of the seven span transmembrane (TM7) adhesion G-protein coupled receptor subclass. It is abundantly expressed in immune cells of myeloid origin and appears to mediate cellular adhesion, migration, and signaling. Based on an analysis showing earlier mortality among
glioblastoma
patients whose tumors highly express
EMR2
, we studied its expression patterns in
glioblastoma
and potential to mediate cellular proliferation and invasion. We performed univariate analysis of overall survival in GBM patients expressing low, moderate, and high amounts of
EMR2
based on publicly available microarray data in the Cancer Genome Atlas (TCGA). Using RT-PCR and western blotting, we studied mRNA and protein expression patterns of
EMR2
, respectively. We then employed siRNA knockdown of
EMR2
in two human
glioblastoma
cell lines expressing high levels of
EMR2
to assess functional effects on cellular proliferation and invasion, in vitro. Kaplan-Meier analysis of TCGA survival data for GBM demonstrated that
EMR2
levels are inversely correlated with overall time until mortality (log rank, P < 0.01).
EMR2
mRNA and protein is variably expressed in primary
glioblastoma
samples and human
glioblastoma
cell lines. When comparing cells transfected with siRNA targeting
EMR2
to those transfected with a negative, scramble control, there was no difference in proliferation over 72 h in the SF767 and G55
glioblastoma
cell lines. However,
EMR2
knockout cells demonstrated an almost 3-fold reduction in migration compared to their negative controls (P < 0.05) in the SF767 cell line, and an almost 2-fold reduction (P < 0.05) in migration in the G55 cell line. We provide evidence that
EMR2
is expressed in
glioblastoma
and has significant functional consequences on cellular invasion, but not proliferation. In light of its ability to promote adhesion and migration in immune cells, our data suggest that
EMR2
may mediate similar phenomena in
glioblastoma
. The invasive phenotype conferred by
EMR2
correlates with clinical data demonstrating poor survival in
glioblastoma
patients who express high levels of
EMR2
in their tumor.
...
PMID:Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. 2150 28
Epidermal growth factor (EGF) module-containing mucin-like receptor 2 (
EMR2
) is a member of the seven span transmembrane adhesion G-protein coupled receptor subclass. This protein is expressed in a subset of
glioblastoma
(
GBM
) cells and associated with an invasive phenotype. The expression pattern and functional significance of
EMR2
in low grade or anaplastic astrocytomas is unknown and our goal was to expand and further define
EMR2
's role in gliomas with an aggressive invasive phenotype. Using the TCGA survival data we describe
EMR2
expression patterns across histologic grades of gliomas and demonstrate an association between increased
EMR2
expression and poor survival (p < 0.05). This data supports prior functional data depicting that
EMR2
-positive neoplasms possess a greater capacity for infiltrative and metastatic spread. Genomic analysis suggests that
EMR2
overexpression is associated with the mesenchymal
GBM
subtype (p < 0.0001). We also demonstrate that immunohistorchemistry is a feasible method for screening
GBM
patients for
EMR2
expression. Protein and mRNA analysis demonstrated variable expression of all isoforms of
EMR2
in all glioma grades, however
GBM
displayed the most diverse isoforms expression pattern as well as the highest expression of the EGF1-5 isoform of
EMR2
. Finally, a correlation of an increased
EMR2
expression after bevacizumab treatment in glioma cells lines is identified. This observation should serve as the impetus for future studies to determine if this up-regulation of
EMR2
plays a role in the observation of the diffuse and increasingly invasive recurrence patterns witnessed in a subset of
GBM
patients after bevacizumab treatment.
...
PMID:Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas. 2520 Aug 31